RIGL

AI Memo

Rigel

As of 2026-09-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

VEPPANU launch execution • 2026-09-30

Base target: $55 / p=50% prob

Biggest risk

The VEPPANU launch is unproven, R289 remains early-stage with meaningful clinical risk, and the termination of the Lilly ocadusertib collaboration reduces one development-partner avenue. Analyst revisions, estimate changes, and post-print market-reaction attribution are unavailable.

Invalidation

Break below $35 or thesis failure.

What would change my mind?

Rigel combines a profitable commercial portfolio with a newly expanded oncology opportunity in VEPPANU and potential R289 clinical optionality. Q2 results and the updated 2026 outlook support a constructive operating trajectory. [#SEC-8K-2026-08-04]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-02

Base target

$55

p=50%

Bull target

$63

p=25%

Bear target

$35

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Execution against 2026 outlook
R289 lower-risk MDS milestones
Rigel combines a profitable commercial portfolio with a newly expanded oncology opportunity in VEPPANU and potential R289 clinical optionality.

BearKey bullets

Commercial execution and the newly expanded portfolio may not meet the updated 2026 outlook.
Low coverage, sparse news, absent social data, and unavailable analyst revisions limit confidence.
R289 may fail to establish a recommended Phase 2 dose or produce supportive preliminary data.

WatchKey bullets

VEPPANU launch execution

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $55 (p=50%)

Target spread vs base: +15% / -36%

Scenario probabilities

Bull Target: $63 (p=25%)Base Target: $55 (p=50%)Bear Target: $35 (p=25%)

Commentary

Primary-source tone is mixed-positive after Q2, supported by profitability, updated revenue guidance, VEPPANU launch preparation, and R289 progress. Coverage is sparse; social sentiment, options data, short interest, employee sentiment, analyst revisions, and market-reaction attribution are unavailable, so this remains a tentative monitoring view. [#SEC-8K-2026-08-04]

As of 2026-09-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Execution against 2026 outlook
R289 lower-risk MDS milestones

Scenarios

Bull Target (Scenario probability)

$63 / p=25% prob

Base Target (Scenario probability)

$55 / p=50% prob

Bear Target (Scenario probability)

$35 / p=25% prob

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

60.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
VEPPANU launch execution
Rigel completed the exclusive global VEPPANU license, paid a $70 million upfront payment, and expected U.S. commercial availability in mid-August 2026. Initial uptake, reimbursement, channel execution, and contribution to guidance remain unverified. [#SEC-8K-2026-08-04]
Prob 65.00% • Move 15.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Execution against 2026 outlook
2026-12-31
Q2 total revenue was $78.7 million, including $67.0 million of net product sales, with $17.3 million of net income. Management provided an updated 2026 revenue outlook of approximately $285-$295 million; delivery remains the near-term validation point. [#SEC-8K-2026-08-04]
Prob 75% • Move 8% • Priced-in 70%

Long-term Catalysts

Months to a year

R289 lower-risk MDS milestones
2026-12-31
The Phase 1b dose-expansion study remains on track to complete enrollment, select a recommended Phase 2 dose in the second half of 2026, and provide preliminary data by year-end. This remains an early-stage, clinically risky opportunity. [#SEC-8K-2026-08-04]
Prob 55% • Move 22% • Priced-in 35%

Risks

Commercial execution and the newly expanded portfolio may not meet the updated 2026 outlook.
Low coverage, sparse news, absent social data, and unavailable analyst revisions limit confidence.
R289 may fail to establish a recommended Phase 2 dose or produce supportive preliminary data.
The Lilly collaboration termination for ocadusertib represents a loss of a partnered development opportunity. [#SEC-8K-2026-05-05]
VEPPANU uptake, reimbursement, channel execution, and contribution to guidance are not yet verified.

Peers

Symbol	Summary
AURA	Loose same-sector, similar-market-cap biotech comparison; relevant mainly for clinical execution and pipeline optionality rather than direct commercial comparability.
IMMX	Loose same-sector, similar-market-cap biotechnology comparison; useful as a broad development-risk reference, not a close peer for Rigel's diversified commercial portfolio.
DRUG	Loose same-sector, similar-market-cap biotech comparison; limited operating comparability and mainly useful for small-cap biotechnology risk context.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-02

Loading AI feed…

Symbol

Summary

AURA

Loose same-sector, similar-market-cap biotech comparison; relevant mainly for clinical execution and pipeline optionality rather than direct commercial comparability.

IMMX

Loose same-sector, similar-market-cap biotechnology comparison; useful as a broad development-risk reference, not a close peer for Rigel's diversified commercial portfolio.

DRUG

Loose same-sector, similar-market-cap biotech comparison; limited operating comparability and mainly useful for small-cap biotechnology risk context.